4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate

Patent metadata

Field	Value
Publication number	US-9957232-B2
Application number	US-44497407-A
Country	US
Kind code	B2
Filing date	Sep 29, 2007
Priority date	Oct 11, 2006
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

The present invention relates to 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.

First claim

What is claimed is:

1. A compound of the formula (II)

2. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically suitable excipients for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

3. A method for the treatment of a hyper-proliferative disorder comprising administering an effective amount of a pharmaceutical composition of claim 2 to a subject in need thereof.

4. The method of claim 3 wherein the hyper-proliferative disorder to be treated is a solid tumor, lymphoma, sarcoma, leukemia or cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid or parathyroid.

5. A pharmaceutical composition comprising the compound of the formula (II) of claim 1 and one or more inert, nontoxic, pharmaceutically suitable excipients.

6. A method for treating hyper-proliferative disorders comprising administering an effective amount of a pharmaceutical composition of claim 5 to a subject in need thereof.

7. A combination comprising the compound of the formula (II) of claim 1 and one or more other pharmaceutical agents.

8. The combination of claim 7 wherein the one or more other pharmaceutical agents are cytotoxic agents, signal transduction inhibitors, anti-cancer agents, or antiemetics.

9. The pharmaceutical composition of claim 5 comprising one or more other pharmaceutical agents.

10. The pharmaceutical composition of claim 9 wherein the one or more other pharmaceutical agents are anti-hyper-proliferative agents, cytotoxic agents, signal transduction inhibitors, anti-cancer agents and/or antiemetics.

11. A pharmaceutical composition comprising a compound of claim 1 of the formula (II) and a pharmaceutically suitable excipient for the treatment of hyper-proliferative disorders.

12. A process for the preparation of the compound of the formula (II)

which comprises dissolution of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl{amino) -3-fluorophenoxy]-N-methylpyridine-2-carboxamide in an inert solvent and adding water until precipitation.

13. A process for the preparation of the compound of the formula (II)

which comprises suspension of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino) -3-fluorophenoxy]-N-methylpyridine-2-carboxamide in an aqueous solvent and then stirring or shaking until conversion to the compound of the formula (II).

14. A pharmaceutical composition comprising a compound of claim 1 of the formula (II) and a pharmaceutically suitable excipient for the treatment of tumors of the digestive tract.

15. A pharmaceutical composition comprising a compound of claim 1 of the formula (II) and a pharmaceutically suitable excipient for the treatment of colorectal cancer.

16. A method for the treatment of tumors of the digestive tract comprising administering an effective amount of a pharmaceutical composition of claim 14 to a subject in need thereof.

17. A method for the treatment of colorectal cancer comprising administering an effective amount of a pharmaceutical composition of claim 15 to a subject in need thereof.

18. A method of claim 4 wherein the
cancer of the breast is invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, or lobular carcinoma in situ;
cancer of the respiratory tract is small-cell and non-small-cell lung carcinoma, bronchial adenoma or pleuropulmonary blastoma;
cancer of the brain is brain stem glioma, hypophtalmic glioma, cerebellar astrocytoma, cerebral astrocytoma, medulloblastoma, ependymoma, neuroectodermal tumor or pineal tumor;
cancer of the male reproductive organ is prostate cancer, testicular cancer, endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer, vulvar cancer or sarcoma of the uterus;
cancer of the digestive tract is anal cancer, colon cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, pancreatic cancer, rectal cancer, small intestine cancer or salivary gland cancer;
cancer of the urinary tract is bladder cancer, penile cancer, kidney cancer, renal pelvis cancer, ureter cancer or urethral cancer;
cancer of the eye is intraocular melanoma or retinoblastoma;
cancer of the liver is hepatocellular carcinoma (liver cell carcinomas with or without fibrolarnellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), or mixed hepatocellular cholangiocarcinoma;
cancer of the skin is squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, or non-melanoma skin cancer;
cancer of the head-and-neck is laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, lip cancer or oral cavity cancer;
the lymphoma is AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, or lymphoma of the central nervous system;
the Sarcoma is sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, or rhabdomyosarcoma;
the Leukemia is acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia.

19. The compound of the formula (II)

which shows in the X-ray diffractometry a peak maximum of the 2 Theta angle of 21.2.

20. The compound of claim 19 which shows in the FIR spectrum a peak maximum of 353 cm −1 .

21. A pharmaceutical composition comprising a compound of claim 20 and one or more pharmaceutically suitable excipients for the treatment of solid tumors, lymphomas, sarcomas, leukaemia's, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

22. A method for the treatment of a hyper-proliferative disorder comprising administering an effective amount of a pharmaceutical composition of claim 21 to a subject in need thereof.

23. A method for the treatment of tumors of the digestive tract comprising administering an effective amount of a pharmaceutical composition of claim 21 to a subject in need thereof.

24. A method for the treatment of colorectal cancer comprising administering an effective amount of a pharmaceutical composition of claim 21 to a subject in need thereof.

25. A compound of the formula (II) of claim 1 which contains H 2 O in an amount of 3.6% by weight.

26. A pharmaceutical composition according to claim 2 wherein the pharmaceutically suitable excipient is water.

27. A pharmaceutical composition according to claim 26 which is a sterile injectable aqueous suspension.

28. A pharmaceutical composition according to claim 2 wherein the pharmaceutically suitable excipient is selected from vegetable oil, arachis oil, olive oil, sesame oil, coconut oil, mineral oil and liquid paraffin.

Assignees

• Grunenberg Alfons
• Stiehl Juergen
• Tenbieg Katharina
• Keil Birgit
• Bayer Healthcare Llc

Inventors

• Grunenberg Alfons
• Stiehl Juergen
• Tenbieg Katharina
• Keil Birgit

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/06

  Antipsoriatics · CPC title